Security Snapshot

BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 Institutional Ownership

CUSIP: 10806XAB8

13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

36

Principal

$451,691,660

Price (% of par)

180.16%

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 3 signals
Principal change
-$44,290,790
Market value change
-$84,802,539
Number of holders
36
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported market price (% of par)
180.16%
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 10806XAB8 - BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 is tracked under CUSIP 10806XAB8.
  • 36 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 46 to 36 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $947,501,000 to $831,061,057.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 36 institutions filings for Q1 2026.

Open SEC evidence

Security key

10806XAB8

Latest holder period

Q1 2026

13F holders

36

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 36 institutional investors reported holding $451,691,660 in principal (par value) of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
21
Latest
Q1 2026
Rows shown
1-21 of 21
Period Principal Value Change Price (% of par) (Median) Investors
2026 Q1 $451,691,660 $831,061,057 -$84,802,539 180.16% 36
2025 Q4 $495,872,450 $947,501,000 -$11,256,841 188.78% 46
2025 Q3 $503,553,600 $706,927,628 -$1,701,713 140.31% 45
2025 Q2 $562,169,600 $702,425,663 +$36,426,925 124.6% 44
2025 Q1 $574,937,600 $656,979,517 +$27,477,843 114.27% 44
2024 Q4 $562,886,600 $590,898,608 -$57,357,159 104.83% 43
2024 Q3 $580,126,900 $598,911,587 +$11,941,965 103.04% 42
2024 Q2 $569,382,900 $575,758,559 +$8,898,618 101.01% 41
2024 Q1 $560,289,110 $603,033,697 +$6,351,656 107.59% 40
2023 Q4 $553,225,000 $670,007,473 +$16,902,300 120.84% 45
2023 Q3 $544,512,610 $527,468,975 +$46,272,601 96.09% 41
2023 Q2 $508,797,285 $400,809,379 -$17,145,882 78.3% 33
2023 Q1 $24,428,285 $29,769,764 -$9,378,870 7329.41% 5
2022 Q4 $532,657,035 $235,817,609 -$942,915 45.0% 31
2022 Q3 $391,715,535 $242,598,365 +$158,207 59.28% 31
2022 Q2 $403,210,035 $228,835,958 -$80,860,371 54.6% 31
2022 Q1 $546,513,489 $332,288,737 -$4,271,771 58.89% 33
2021 Q4 $522,000,515 $380,362,858 -$37,345,964 73.22% 38
2021 Q3 $532,460,742 $739,286,875 -$47,139,012 138.21% 40
2021 Q2 $570,332,000 $936,089,296 +$76,483,812 164.13% 39
2021 Q1 $519,285,000 $858,858,248 +$842,687,530 165.39% 35
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .